Barclays
CTNM

Barclays’s Contineum Therapeutics CTNM Stock Holding History

Barclays’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$953K Buy
58,173
+14,215
+32% +$186K ﹤0.01% 2816
2026
Q1 		$574K Sell
43,958
-15,549
-26% -$209K ﹤0.01% 3107
2025
Q4 		$680K Buy
59,507
+53,031
+819% +$605K ﹤0.01% 3681
2025
Q3 		$76.1K Buy
6,476
+4,744
+274% +$38.2K ﹤0.01% 4681
2025
Q2 		$6.88K Sell
1,732
-9,351
-84% -$40.6K ﹤0.01% 4944
2025
Q1 		$77.4K Sell
11,083
-5,203
-32% -$47.3K ﹤0.01% 4480
2024
Q4 		$239K Buy
16,286
+7,978
+96% +$126K ﹤0.01% 4222
2024
Q3 		$159K Buy
8,308
+5,925
+249% +$114K ﹤0.01% 4411
2024
Q2 		$42K Buy
+2,383
New +$38.4K ﹤0.01% 4271

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Barclays's CTNM Position: Q2 2026 in Review

Barclays increased its Contineum Therapeutics (CTNM) stake by 32% in Q2 2026, buying an estimated $186K and bringing the position to 58,173 shares worth $953K. The position accounts for ﹤0.01% of the portfolio, ranked #2816.

Barclays first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Barclays held 58,173 shares of Contineum Therapeutics worth $953K as of Q2 2026.
  • Barclays bought 14,215 Contineum Therapeutics shares in Q2 2026, an estimated $186K.
  • Contineum Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2816 holding.
  • Barclays first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.